# A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record

Study · id `cardio:ct-nct06642272` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06642272](<https://clinicaltrials.gov/study/NCT06642272>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06642272

Browse, organ or system: Heart; Kidneys; Metabolism  
Browse, condition area: Heart failure; Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 17200 participants.

## Technical summary

Registry record NCT06642272. Randomized; no masking; primary purpose treatment. Start 2024-10-10 (actual); primary completion 2028-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 17200 participants (planned count; ClinicalTrials.gov record NCT06642272, source copy `cardio:ctgov-nct06642272-2026-09-18`, retrieved 2026-10-26)
- Started: 2024-10-10 (actual) (ClinicalTrials.gov record NCT06642272, source copy `cardio:ctgov-nct06642272-2026-09-18`, retrieved 2026-10-26)
- Primary completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT06642272, source copy `cardio:ctgov-nct06642272-2026-09-18`, retrieved 2026-10-26)
- Completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT06642272, source copy `cardio:ctgov-nct06642272-2026-09-18`, retrieved 2026-10-26)
- Countries: Denmark (ClinicalTrials.gov record NCT06642272, source copy `cardio:ctgov-nct06642272-2026-09-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06642272-2026-09-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record
- Acronym: APPLE TREE
- Condition: Diabetes Mellitus, Type 2
- Condition: Heart Failure
- Condition: Chronic Kidney Diseases
- Intervention (Drug): Empagliflozin 10 MG
- Intervention (Drug): Dapagliflozin 10 MG
- Lead sponsor: Herlev and Gentofte Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Herlev and Gentofte Hospital (`cardio:org-herlev-and-gentofte-hospital`)

## Provenance

Content hash: e6e6c6edf86f2d84f0df62b09c9feb9ef7a5ff24c765351fa27f57756c4ecbb4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
